Prothena to Participate in Upcoming Healthcare Conferences
Prothena Corporation (NASDAQ:PRTA) announced participation in upcoming investor conferences, highlighting its late-stage clinical biotechnology focus on protein dysregulation. Key events include:
- Citi’s 17th Annual BioPharma Conference on September 8, 1x1 investor meetings.
- Morgan Stanley 20th Annual Global Healthcare Conference on September 13, with a fireside chat at 5:15 PM ET.
- H.C. Wainwright 24th Annual Global Investment Conference on September 14, fireside chat at 9:00 AM ET.
- Cantor Neurology & Psychology Conference on October 6, 1x1 investor meetings.
Live webcasts will be available on their website.
- None.
- None.
DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following upcoming investor conferences:
- Citi’s 17th Annual BioPharma Conference on Thursday, September 8, 1x1 investor meetings will be held
- Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, a fireside chat will be held at 5:15 PM ET
- H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, a fireside chat will be held at 9:00 AM ET
- Cantor Neurology & Psychology Conference on Thursday, October 6, 1x1 investor meetings will be held
A live webcast of the fireside chats can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
Media and Investor Contact:
Investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com
Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com
FAQ
What investor conferences is Prothena participating in September 2022?
What time is Prothena's fireside chat at the Morgan Stanley conference?
Where can I access the live webcasts for Prothena's presentations?
What is Prothena Corporation's focus area in biotechnology?
When is Prothena's participation at the Cantor Neurology & Psychology Conference?
